Biological correlates of acute hypersensitivity events with DAB389IL-2 (denileukin diftitox, ONTAK®) in cutaneous T-cell lymphoma: Decreased frequency and severity with steroid premedication

Clinical Lymphoma

Volumn 1, Issue 4, 2001, Pages 298-302

  Foss, Francine M ^a   Bacha, Patricia ^b   Osann, Kathryn E ^c   Demierre, Marie France ^d   Bell, Tracy ^a   Kuzel, Timothy ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BOSTON MEDICAL CENTER   (United States)

Author keywords

DAB389IL 2; Hypersensitivity events; Steroid premedication; Vascular leak syndrome

Indexed keywords

ANTIEMETIC AGENT; CYTOKINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DIPHENHYDRAMINE; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR; PARACETAMOL; PREDNISONE; STEROID;

ACUTE DISEASE; ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EXPERIENCE; FATIGUE; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; INCIDENCE; INFECTION; LYMPHOMA CELL; MALE; MORBIDITY; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PREMEDICATION; RASH; SEZARY SYNDROME; SKIN LYMPHOMA; T CELL LYMPHOMA; THORAX PAIN; VASCULAR DISEASE;

EID: 0035054648     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2001.n.005     Document Type: Article

References (16)

1. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein
2. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein
3. Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells
4. Inhibition of coated pit formation in Hep2 cells blocks the cytotoxicity of diphtheria toxin but not that of ricin toxin
5. Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: Electron microscopic evaluation
6. A possible role for Na+, K+-ATPase in regulating ATP-dependent endosome acidification
7. Diphtheria toxin fragment forms large pores in phospholipid bilayer membranes
8. Diphtheria toxin forms transmembrane channels in planar lipid bilayers
9. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells
10. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2
11. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides
12. Quality of life is significantly improved in CTCL patients who responded to DAB389-IL2 (ONTAK) fusion protein
13. Pivotal phase III trial of two doses of DAB389-IL2 (ONTAK) for the treatment of cutaneous T-cell lymphoma
14. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome
15. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma